News
Hiring Dr. Jamie Paterson as CEO
and Closing Financing Round
feb 2, 2010
Viroblock SA, a start-up dedicated to developing and commercializing a new generation of anti-viral products, today announced that Dr. Jamie Paterson will join Viroblock as Chief Executive Officer (CEO)...
99% Boost of Efficacy of Facemasks against H5N1
MaY 5, 2009
Viroblock SA announces that its antiviral products boosts the efficacy of facemasks by at least 99.0%, i.e. 100 times better and a peak performance of 1000 times, against avian influenza virus H5N1...
Viroblock is a Geneva-based startup company founded in October 2005. The goal of the company is to develop and commercialize a brand new generation of antiviral products with a novel mechanism of action against enveloped viruses, which include major human pathogens such as human and avian influenzas, SARS virus and the AIDS virus. Given their particular antiviral mechanism, Viroblock’s products should have a broad spectrum of action across virus families and should not lead to viral resistance.
The W. A. de Vigier Foundation nominated Viroblock as one of the 10 best technology projects of the year 2006, and the Selection Committee of the Swiss Tech Tour 2007 rated Viroblock as one of the top technology companies in Switzerland. Viroblock is based at the incubator FONGIT in Plan-les-Ouates, Geneva.
